文献速递神经肿瘤

WHO II级脑膜瘤辅助放疗与总生存获益相关

Overall survival benefit associated with adjuvant radiotherapy in WHO grade II meningioma.
PubMed 文献 · Neuro Oncol · 2017-01-01

基于美国国家癌症数据库2009至2012年诊断的2515例WHO II级非典型脑膜瘤患者,比较次全切除或全切除后辅助放疗与未放疗的总生存差异。倾向评分匹配后多因素Cox回归显示,次全切除后辅助放疗与总生存改善显著相关(调整风险比0.590,P=0.045),全切除后辅助放疗与总生存改善无显著关联(调整风险比1.093,P=0.737)。

要点

  • 次全切除后辅助放疗与总生存改善显著相关(调整风险比0.590,P=0.045)。
  • 全切除后辅助放疗与总生存改善无显著关联(调整风险比1.093,P=0.737)。
  • 全切除较次全切除与总生存改善相关。

核心结论

  • 尽管辅助放疗能否减少非典型脑膜瘤术后复发尚无共识,本研究观察到次全切除后辅助放疗较未放疗显著改善总生存。

研究设计与样本

  • 使用美国国家癌症数据库识别2009年至2012年诊断的2515例WHO II级非典型脑膜瘤患者,均接受次全切除或全切除,伴或不伴辅助放疗。
  • 先按辅助放疗状态分层,在次全切除或全切除队列中行倾向评分匹配以平衡年龄、诊断年份、性别、种族、组织学和肿瘤大小等协变量。
  • 随后采用Cox比例风险模型多因素回归及Kaplan-Meier生存曲线与log-rank检验评估辅助放疗相关的总生存差异。

主要发现

  • 全切除较次全切除与总生存改善相关。
  • 亚组分析中,次全切除后辅助放疗较未辅助放疗与总生存改善显著相关(调整风险比0.590,P=0.045)。
  • 全切除后辅助放疗与总生存改善无显著关联(调整风险比1.093,P=0.737)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Adjuvant radiotherapy (RT) after surgical resection of World Health Organization (WHO) grade II meningioma, also known as atypical meningioma (AM), is a topic of controversy. The purpose of this study is to compare overall survival (OS) with or without adjuvant RT after subtotal resection (STR) or gross total resection (GTR) in AM patients diagnosed according to the 2007 WHO classification. METHODS: The National Cancer Database was used to identify 2515 patients who were diagnosed with AM between 2009 and 2012 and underwent STR or GTR with or without adjuvant RT. Propensity score matching was first applied to balance covariates including age, year of diagnosis, sex, race, histology, and tumor size in STR or GTR cohorts stratified by adjuvant RT status. Multivariate regression according to the Cox proportional hazards model and Kaplan-Meier survival plots with log-rank test were then used to evaluate OS difference associated with adjuvant RT. RESULTS: GTR is associated with improved OS compared with STR. In the subgroup analysis, adjuvant RT in patients who underwent STR demonstrated significant association with improved OS compared with no adjuvant RT (adjusted hazard ratio [AHR] 0.590, P = .045); however, adjuvant RT is not associated with improved OS in patients who underwent GTR (AHR 1.093, P = .737). CONCLUSIONS: Despite the lack of consensus on whether adjuvant RT reduces recurrence after surgical resection of AM, our study observed significantly improved OS with adjuvant RT compared with no adjuvant RT after STR.

来源:Neuro Oncol,查看原文。版权归原作者所有。

引用

  1. Wang C, Kaprealian TB, Suh JH, et al. Overall survival benefit associated with adjuvant radiotherapy in WHO grade II meningioma. Neuro Oncol. 2017. PMID: 28371851. doi:10.1093/neuonc/nox007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。